Charles Schwab
LENZ

Charles Schwab’s LENZ Therapeutics LENZ Stock Holding History

Charles Schwab’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
172,807
+23,263
+16% +$188K ﹤0.01% 3010
2026
Q1 		$1.37M Sell
149,544
-19,578
-12% -$275K ﹤0.01% 2810
2025
Q4 		$2.71M Buy
169,122
+8,596
+5% +$251K ﹤0.01% 2669
2025
Q3 		$7.48M Buy
160,526
+18,414
+13% +$677K ﹤0.01% 2254
2025
Q2 		$4.17M Buy
142,112
+18,066
+15% +$491K ﹤0.01% 2405
2025
Q1 		$3.19M Sell
124,046
-3,150
-2% -$77.6K ﹤0.01% 2460
2024
Q4 		$3.67M Buy
127,196
+3,825
+3% +$117K ﹤0.01% 2479
2024
Q3 		$2.93M Buy
123,371
+81,901
+197% +$1.82M ﹤0.01% 2594
2024
Q2 		$717K Buy
41,470
+29,787
+255% +$520K ﹤0.01% 3048
2024
Q1 		$261K Sell
11,683
-1
-0% -$21 ﹤0.01% 3200
2023
Q4 		$214K Hold
11,684
– – ﹤0.01% 3270
2023
Q3 		$203K Hold
11,684
– – ﹤0.01% 3288
2023
Q2 		$213K Buy
11,684
+9,150
+361% +$183K ﹤0.01% 3297
2023
Q1 		$43.5K Hold
2,534
– – ﹤0.01% 3372
2022
Q4 		$58.9K Hold
2,534
– – ﹤0.01% 3328
2022
Q3 		$57K Buy
+2,534
New +$60.4K ﹤0.01% 3301
2022
Q2 		– Sell
-10,243
Closed -$366K – 3657
2022
Q1 		$366K Buy
10,243
+4,156
+68% +$260K ﹤0.01% 3167
2021
Q4 		$530K Buy
6,087
+402
+7% +$33.3K ﹤0.01% 3126
2021
Q3 		$653K Buy
+5,685
New +$842K ﹤0.01% 3052

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Charles Schwab's LENZ Position: Q2 2026 in Review

Charles Schwab increased its LENZ Therapeutics (LENZ) stake by 16% in Q2 2026, buying an estimated $188K and bringing the position to 172,807 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #3010.

Charles Schwab first reported a position in LENZ in Q3 2021 and has held it in 19 quarters since. The position peaked at $7.48M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Charles Schwab held 172,807 shares of LENZ Therapeutics worth $982K as of Q2 2026.
  • Charles Schwab bought 23,263 LENZ Therapeutics shares in Q2 2026, an estimated $188K.
  • LENZ Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3010 holding.
  • Charles Schwab first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Charles Schwab's LENZ Therapeutics position peaked at $7.48M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.